-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 1, Puli Pharmaceuticals announced that the company has recently received a notice of approval for azithromycin for injection issued by the Thai Food and Drug Administration.
Azithromycin for injection is suitable for the following infections caused by sensitive pathogens:
1.
Patients who are caused by pathogenic bacteria such as Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus, or Streptococcus pneumoniae, and the initial treatment requires intravenous administration.
2.
Patients who are caused by Chlamydia trachomatis, Neisseria gonorrhoeae, or Mycoplasma hominis and who require intravenous administration for the initial treatment.